Renal Cell Carcinoma | Clinical

Lee and McGregor Discuss Methods to Integrate New Approaches in RCC Treatment

June 25, 2022

During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.

Evaluating First-Line Treatment Options for Metastatic ccRCC

June 19, 2022

During a Targeted Oncology case-based roundtable event, Chandler Park, MD, discussed the preferred first-line treatment options including tyrosine kinase inhibitor/immunotherapy combinations for metastatic clear cell renal cell carcinoma.

Triplet Combination Data Add Evidence to Clinical Activity in aRCC

June 16, 2022

Data regarding the triplet combination of nivolumab, ipilimumab, and cabozantinib show clinical activity across multiple tumor types, giving a preview of future outcomes in patients with untreated, advanced renal cell carcinoma.